|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
50,230,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Icosavax is a biopharmaceutical company utilizing its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Co.'s pipeline includes vaccine candidates targeting some of viral causes of pneumonia. Co.'s vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus, and IVX-241, a vaccine candidate designed to target human metapneumovirus. Co. is developing additional vaccine candidates to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
225,965 |
262,386 |
481,304 |
Total Sell Value |
$0 |
$3,496,502 |
$3,819,051 |
$6,446,684 |
Total People Sold |
0 |
4 |
5 |
7 |
Total Sell Transactions |
0 |
8 |
13 |
44 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kanesa-Thasan Niranjan |
Chief Medical Officer |
|
2023-01-04 |
4 |
S |
$15.70 |
$1,670,460 |
D/D |
(106,373) |
223,980 |
|
- |
|
Kanesa-Thasan Niranjan |
Chief Medical Officer |
|
2023-01-04 |
4 |
OE |
$0.84 |
$249,298 |
D/D |
106,373 |
330,353 |
|
- |
|
Holtzman Douglas |
Chief Scientific Officer |
|
2022-12-15 |
4 |
S |
$11.14 |
$218,963 |
I/I |
(19,648) |
2,792 |
|
- |
|
Bekiroglu Elizabeth |
General Counsel & Corp. Sec. |
|
2022-09-08 |
4 |
AS |
$4.87 |
$8,835 |
D/D |
(1,813) |
108,929 |
|
- |
|
Richardson Charles E |
SVP, Technical Operations |
|
2022-08-02 |
4 |
AS |
$6.70 |
$2,487 |
D/D |
(371) |
165,168 |
|
- |
|
Kanesa-Thasan Niranjan |
Chief Medical Officer |
|
2022-08-02 |
4 |
AS |
$6.70 |
$3,640 |
D/D |
(543) |
239,314 |
|
- |
|
Russo Thomas Joseph |
Chief Financial Officer |
|
2022-08-02 |
4 |
AS |
$6.70 |
$3,318 |
D/D |
(495) |
48,921 |
|
- |
|
Holtzman Douglas |
Chief Scientific Officer |
|
2022-08-02 |
4 |
AS |
$6.70 |
$3,037 |
D/D |
(453) |
293,258 |
|
- |
|
Simpson Adam K. |
Chief Executive Officer |
|
2022-08-02 |
4 |
AS |
$6.70 |
$12,764 |
D/D |
(1,904) |
291,869 |
|
- |
|
Cearley Cassia |
Chief Business Officer |
|
2022-08-02 |
4 |
AS |
$6.70 |
$2,031 |
D/D |
(303) |
131,738 |
|
- |
|
Richardson Charles E |
SVP, Technical Operations |
|
2022-08-01 |
4 |
AS |
$6.64 |
$9,080 |
D/D |
(1,368) |
165,539 |
|
- |
|
Kanesa-Thasan Niranjan |
Chief Medical Officer |
|
2022-08-01 |
4 |
AS |
$6.64 |
$13,281 |
D/D |
(2,001) |
239,857 |
|
- |
|
Russo Thomas Joseph |
Chief Financial Officer |
|
2022-08-01 |
4 |
AS |
$6.64 |
$12,113 |
D/D |
(1,825) |
49,416 |
|
- |
|
Holtzman Douglas |
Chief Scientific Officer |
|
2022-08-01 |
4 |
AS |
$6.64 |
$61,973 |
D/D |
(9,337) |
293,711 |
|
- |
|
Simpson Adam K. |
Chief Executive Officer |
|
2022-08-01 |
4 |
AS |
$6.64 |
$46,575 |
D/D |
(7,017) |
293,772 |
|
- |
|
Cearley Cassia |
Chief Business Officer |
|
2022-08-01 |
4 |
AS |
$6.64 |
$7,421 |
D/D |
(1,118) |
132,041 |
|
- |
|
Richardson Charles E |
SVP, Technical Operations |
|
2022-07-29 |
4 |
AS |
$7.11 |
$3,405 |
D/D |
(479) |
166,907 |
|
- |
|
Kanesa-Thasan Niranjan |
Chief Medical Officer |
|
2022-07-29 |
4 |
AS |
$7.11 |
$4,982 |
D/D |
(701) |
241,858 |
|
- |
|
Russo Thomas Joseph |
Chief Financial Officer |
|
2022-07-29 |
4 |
AS |
$7.11 |
$4,542 |
D/D |
(639) |
51,241 |
|
- |
|
Holtzman Douglas |
Chief Scientific Officer |
|
2022-07-29 |
4 |
AS |
$7.11 |
$4,158 |
D/D |
(585) |
303,048 |
|
- |
|
Simpson Adam K. |
Chief Executive Officer |
|
2022-07-29 |
4 |
AS |
$7.11 |
$17,456 |
D/D |
(2,456) |
300,789 |
|
- |
|
Cearley Cassia |
Chief Business Officer |
|
2022-07-29 |
4 |
AS |
$7.11 |
$2,779 |
D/D |
(391) |
133,159 |
|
- |
|
Simpson Adam K. |
Chief Executive Officer |
|
2022-07-01 |
4 |
OE |
$0.84 |
$6,035 |
D/D |
7,185 |
303,245 |
|
- |
|
Mcdade Mark |
Director |
|
2022-04-01 |
4 |
B |
$7.10 |
$299,798 |
D/D |
42,225 |
50,243 |
2.39 |
- |
|
Shah Rajeev M. |
Director |
|
2022-03-29 |
4 |
B |
$4.75 |
$42,271 |
I/I |
8,900 |
5,963,565 |
2.25 |
- |
|
119 Records found
|
|
Page 3 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|